Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing
08. September 2020 12:10 ET
|
Protagenic Therapeutics, Inc.
Capital to be Used to Complete IND Filing and Commence Phase I/II Clinical Trial for Lead Clinical Compound PT00114 NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc....